3-bromo-N-butylimidazo[1,2-b]pyridazin-6-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-bromo-N-butylimidazo[1,2-b]pyridazin-6-amine
• 英文别名: 6-N-(butylamino)-3-bromoimidazo[1,2-b]pyridazine；6-(butylamino)imidazo[1,2-b]pyridazine-3-bromide；(3-bromo-imidazo[1,2-b]pyridazin-6-yl)-butyl-amine；3-Bromo-6-(butylamino)imidazo[1,2-b]pyridazine
• 化学式: C₁₀H₁₃BrN₄
• 分子量: 269.144
• InChiKey: OYYSHVCYICCZID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-N-butylimidazo[1,2-b]pyridazin-6-amine 在 4-二甲氨基吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 生成
  参考文献：
  名称：

  Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models

  摘要：

  We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.115
• 作为产物：
  描述：

  3-溴-6-氯咪唑并[1,2-b]哒嗪 、 正丁胺 在 苄基三乙基氯化铵 、 cesium fluoride 作用下， 以 二甲基亚砜 为溶剂， 以94 %的产率得到3-bromo-N-butylimidazo[1,2-b]pyridazin-6-amine
  参考文献：
  名称：

  C-6 胺化 3-溴咪唑并[1,2-b]哒嗪的高效合成

  摘要：

  在 DMSO 中于 100 ° 下用各种 1° 或 2° 烷基胺（2.0 当量）、CsF（1.0 当量）和 BnNEt3Cl（10 mol%）处理 3-溴-6-氯咪唑并[1,2-b]哒嗪C（24小时）给出了对应的...

  DOI：

  10.1080/00397911.2023.2284350

文献信息

• [EN] IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF<br/>[FR] COMPOSÉS À BASE D'IMIDAZO [1, 2-B] PYRIDAZINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2013134219A1

  公开（公告）日：2013-09-12

  Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  基于咪唑并[1,2-b]吡啶嗪的化合物的公式（I）被披露，其中R1、R2和R3在此处被定义。还披露了包含这些化合物的组合物以及它们用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和紊乱的方法。
• [EN] OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF<br/>[FR] COMPOSÉS D'OXAZOLIDINONE ET LEURS DÉRIVÉS
  申请人：AMGEN INC

  公开号：WO2013134079A1

  公开（公告）日：2013-09-12

  Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.

  式(I)和式(II)的化合物是坦克酶的有用抑制剂。式(I)和式(II)的化合物具有以下结构：其中变量的定义在此提供。
• [EN] NITROXY DERIVATIVES OF SOFT STEROIDS<br/>[FR] DÉRIVÉS NITROXY DE STÉROÏDES DOUX
  申请人：BAUSCH & LOMB

  公开号：WO2013133980A1

  公开（公告）日：2013-09-12

  A compound of formula (I) or a pharmaceutically acceptable salt thereof, and an ophthalmic composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to the use of the ophthalmic compositions for treating inflammatory conditions of the palpebral or bulbar conjunctiva, cornea and anterior segment of the globe, and to ameliorate inflammation associated with corneal injury.

  一种具有化学式（I）的化合物或其药用可接受的盐，以及包含具有化学式（I）的化合物或其药用可接受的盐的眼科组合物。本发明还涉及将眼科组合物用于治疗睑板或球结膜、角膜和眼球前节的炎症病症，以及缓解与角膜损伤相关的炎症。
• Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
  申请人：Bi Yingzhi

  公开号：US08969565B2

  公开（公告）日：2015-03-03

  Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  公开了基于咪唑并[1,2-b]吡啶的化合物的公式：其中R1，R2和R3在此定义。还公开了包含该化合物的组合物以及使用它们治疗、管理和/或预防适配器相关激酶1活性介导的疾病和紊乱的方法。
• IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
  申请人：BI Yingzhi

  公开号：US20130245021A1

  公开（公告）日：2013-09-19

  Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R 1 , R 2 and R 3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  本发明揭示了基于咪唑并[1,2-b]吡啶的化合物，其化学式如下：其中R1、R2和R3在此定义。本发明还揭示了包含这些化合物的组合物以及它们的使用方法，用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和障碍。